Azitra, Inc., a Branford-based clinical stage biopharmaceutical company focused on precision dermatology reported first-quarter 2026 results that included clinical expansion, new patent protection, and a broadened commercial strategy.
Azitra, Inc. added MD Anderson Cancer Center as a clinical site for its Phase 1/2 trial of ATR-04, which targets skin rash associated with EGFR inhibitor therapy in cancer patients. The company said the addition is intended to improve patient access and support efficient trial execution.
Francisco Salva, CEO of Azitra, said, "Notably, we significantly grew the clinical footprint for our Phase 1/2 Trial of ATR-04 targeting EGFRi-associated skin rash by adding the world-renowned MD Anderson Cancer Center, which is one of the world's premier oncology institutions. We believe the addition of MD Anderson will serve to enhance patient access and support efficient trial execution in EGFR inhibitor-associated rash, a condition impacting the majority of patients receiving these therapies."
The company also secured a new U.S. patent covering ATR-12, its lead product candidate for Netherton syndrome, a rare and potentially fatal chronic skin disease with no approved treatments. Topline data from the ongoing Phase 1b trial in adult patients is expected in the second half of 2026.
"We are also excited to report the recent issuance of a new U.S. patent providing broad protection for our lead product, ATR-12, which we are advancing in a Phase 1b clinical trial for Netherton syndrome," said Salva. "With a strengthened balance sheet, expanding clinical execution, and multiple near-term catalysts, we believe Azitra is well positioned to drive continued progress across both our therapeutic pipeline and emerging cosmeceutical platform."
Azitra also launched a new cosmeceutical initiative leveraging its proprietary filaggrin protein and peptide technologies, targeting the appearance of fine lines, wrinkles, dry sensitive skin, and eczema-like rashes. The company reported a net loss of $3.9 million for the quarter and held $10.1 million in cash as of March 31, 2026.
